866-997-4948(US-Canada Toll Free)

Malaria Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Mar 2013

Category :

Oncology

No. of Pages : 269 Pages


Global Markets Directs, \'Malaria Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Malaria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malaria. 

Malaria Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Malaria.
  • A review of the Malaria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Malaria pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Malaria.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Malaria pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Malaria Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Malaria 12
Malaria Therapeutics under Development by Companies 14
Malaria Therapeutics under Investigation by Universities/Institutes 20
Late Stage Products 23
Comparative Analysis 23
Mid Clinical Stage Products 24
Comparative Analysis 24
Early Clinical Stage Products 25
Comparative Analysis 25
Discovery and Pre-Clinical Stage Products 26
Comparative Analysis 26
Malaria Therapeutics Products under Development by Companies 27
Malaria Therapeutics Products under Investigation by Universities/Institutes 33
Companies Involved in Malaria Therapeutics Development 37
Genzyme Corporation 37
Sanofi-Aventis 38
AstraZeneca PLC 39
GlaxoSmithKline plc 40
Inovio Biomedical Corporation 41
Novartis AG 42
Actelion Ltd 43
Eisai Co., Ltd. 44
Pfizer Inc. 45
Ranbaxy Laboratories Limited 46
Aduro BioTech 47
CEL-SCI Corporation 48
Crucell N.V. 49
Hollis-Eden Pharmaceuticals, Inc. 50
Mymetics Corporation 51
Cleveland BioLabs, Inc. 52
Alnylam Pharmaceuticals, Inc 53
IPCA Laboratories Limited 54
Lipoxen PLC 55
Raptor Pharmaceuticals Corp. 56
PolyMedix, Inc. 57
Affitech A/S 58
Colby Pharmaceutical Company 59
Bharat Biotech International Limited 60
Jenrin Discovery, Inc. 61
Mucosis B.V. 62
Protein Potential, LLC 63
Anacor Pharmaceuticals, Inc. 64
Telormedix SA 65
Dilafor AB 66
Okairos 67
Ferrer Internacional S.A. 68
Chimerix, Inc. 69
Phage Biotechnology Corporation 70
Sanaria Inc. 71
NovaLead Pharma Pvt. Ltd. 72
ImmunoVaccine Technologies Inc. 73
Acetylon Pharmaceuticals, Inc. 74
Etubics Corporation 75
iBio, Inc. 76
PepTcell Limited 77
Genocea Biosciences, Inc. 78
Hawaii Biotech, Inc. 79
Sigma-Tau Pharmaceuticals, Inc. 80
Selecta Biosciences, Inc. 81
GlaxoSmithKline Inc. 82
Pfenex Inc. 83
NeED Pharma s.r.l. 84
VLP Biotech, Inc. 85
Jomaa Pharma GmbH 86
Malaria Therapeutics Assessment 87
Assessment by Monotherapy Products 87
Assessment by Combination Products 88
Assessment by Route of Administration 89
Assessment by Molecule Type 91
Drug Profiles 93
albitiazolium bromide - Drug Profile 93
ferroquine - Drug Profile 94
Malaria Vaccine - Drug Profile 95
tafenoquine - Drug Profile 97
PMX-30024 - Drug Profile 99
CEL-1000 - Drug Profile 100
Malaria DNA Vaccine - Drug Profile 103
artesunate - Drug Profile 104
Pyramax - Drug Profile 105
OZ-439 - Drug Profile 107
P218 DHFR - Drug Profile 108
VLD-517 - Drug Profile 109
BCX-4945 - Drug Profile 110
(arterolane maleate + piperaquine phosphate) - Drug Profile 111
JD-3000 Series - Drug Profile 112
Malarial Vaccine - Drug Profile 113
EP-1300 - Drug Profile 114
Malaria Vaccine - Drug Profile 115
Vaccine For Mosquito-Borne Disease - Drug Profile 116
Malaria Research Program - Drug Profile 117
PfSPZ Vaccine - Drug Profile 118
Malaria Vaccine Programme - Drug Profile 120
artemether - Drug Profile 121
(azithromycin + chloroquine) - Drug Profile 122
PEV-3 - Drug Profile 124
PEV-3 - Drug Profile 126
azithromycin + (sulfadoxine + pyrimethamine) - Drug Profile 128
NMRC-M3V-Ad-PfCA - Drug Profile 130
(trimethoprim + sulfamethoxazole) - Drug Profile 132
GSK-257049 + [AS02A] - Drug Profile 133
GSK-257049 + [AS01B] - Drug Profile 134
Mosquirix - Drug Profile 135
EBA-175 RII-NG Malaria Vaccine - Drug Profile 138
(BSAM2/Alhydrogel + CPG 7909) - Drug Profile 139
AdCh63 MSP1 + AdCh63 ME-TRAP + MVA MSP1 + MVA ME-TRAP - Drug Profile 140
HE-2000 - Drug Profile 142
PMX-70008 - Drug Profile 144
Malaria Vaccine - Drug Profile 145
Malaria Vaccine - Drug Profile 146
Malaria Vaccine - Drug Profile 148
IMX-MSP3 - Drug Profile 149
IMX-MSP4 - Drug Profile 150
fosmidomycin - Drug Profile 151
sevuparin sodium - Drug Profile 153
TMX-201 - Drug Profile 154
Pf-27-LSP - Drug Profile 155
AN-3661 - Drug Profile 156
Lm-Malaria - Drug Profile 157
MSP3-LSP/ALOH - Drug Profile 158
Nonadjuvanted Polypeptide Nanoparticle Vaccine - Drug Profile 159
JVRS-100 + [Malaria Vaccine] - Drug Profile 160
RCQ Anti-Malaria Program - Drug Profile 161
Modified Acridone Anti-malaria Program - Drug Profile 162
manzamine - Drug Profile 163
Drug For Malaria - Drug Profile 164
Drug For Malaria - Drug Profile 165
KAE-609 - Drug Profile 166
BPH-703 - Drug Profile 168
Malaria NG Pf - Drug Profile 169
Malaria Vaccine - Drug Profile 170
Malaria Vaccine - Drug Profile 171
Xenomycin - Drug Profile 172
Neglected Diseases Program - Drug Profile 173
PVrII - Drug Profile 174
Carbohydrate Malaria Vaccine - Drug Profile 175
Targeted synthetic vaccine particles for malaria - Drug Profile 176
ML-276 - Drug Profile 177
cysteamine + [artemisinin] - Drug Profile 178
CDRI-97/78 - Drug Profile 179
CDRI-99/411 - Drug Profile 180
AnAPN1 - Drug Profile 181
CSP RI Conjugates - Drug Profile 182
EBA-Rh - Drug Profile 183
Adjuvanted CSP - Drug Profile 184
CSP - Drug Profile 185
PvCSP-AS01 - Drug Profile 186
PvDBPII Vaccine - Drug Profile 187
Vaccine Adjuvant - Drug Profile 188
Malaria Vaccine - Drug Profile 189
Placental Malaria Vaccine - Drug Profile 190
Drug For Malaria - Drug Profile 191
IMX313-Ag - Drug Profile 192
Malaria Program - Drug Profile 193
Malaria Vaccine - Drug Profile 194
E-6446 - Drug Profile 195
Artemisinin-Based Combined Therapy - Drug Profile 196
Malaria Vaccine - Drug Profile 197
crotoxin B - Drug Profile 198
ND-901 - Drug Profile 199
Drug For Malaria - Drug Profile 200
Chimigen Malaria Vaccine - Drug Profile 201
SOM-0888 - Drug Profile 202
Prevenquito - Drug Profile 203
KAF-156 - Drug Profile 204
BIX-01294 - Drug Profile 205
TM2-115 - Drug Profile 206
Malaria Vaccine Program - Drug Profile 207
Calpain Inhibitor - Drug Profile 208
Malaria Vaccine - Drug Profile 209
Chalcone Derivatives - Drug Profile 210
DSM-265 - Drug Profile 211
Malaria Program - Drug Profile 212
Malaria Program 1 - Drug Profile 213
GENZ-644442 - Drug Profile 214
Malaria Program 2 - Drug Profile 215
GENZ-668764 - Drug Profile 216
ELQ-300 - Drug Profile 217
21A092 - Drug Profile 218
MMV-390048 - Drug Profile 219
GNF-156 - Drug Profile 220
Malaria Program - Drug Profile 221
Malaria Program - Drug Profile 222
Malaria Program-2 - Drug Profile 223
Heterocycle Series - Drug Profile 224
Malaria Program - Drug Profile 225
Malaria Program 1 - Drug Profile 226
21A102 Backup - Drug Profile 227
Malaria Program - Drug Profile 228
21A092 Back-Up - Drug Profile 229
Malaria Program - Drug Profile 230
Protein Kinase Deregulators - Drug Profile 231
Plasmodium Dihydrooratate Dehydrogenase Inhibitors - Drug Profile 232
RKA-182 - Drug Profile 233
Drug For Parasitic Diseases - Drug Profile 234
Malaria Therapeutics Drug Profile Updates 235
Malaria Therapeutics Discontinued Products 243
Malaria Therapeutics - Dormant Products 245
Malaria Product Development Milestones 250
Featured News & Press Releases 250

Appendix 259
Methodology 259
Coverage 259
Secondary Research 259
Primary Research 259
Expert Panel Validation 259
Contact Us 260
Disclaimer 260

List of Table


Number of Products Under Development for Malaria, H1 2013 21
Products under Development for Malaria Comparative Analysis, H1 2013 22
Number of Products under Development by Companies, H1 2013 24
Number of Products under Development by Companies, H1 2013 (Contd..1) 25
Number of Products under Development by Companies, H1 2013 (Contd..2) 26
Number of Products under Development by Companies, H1 2013 (Contd..3) 27
Number of Products under Development by Companies, H1 2013 (Contd..4) 28
Number of Products under Investigation by Universities/Institutes, H1 2013 30
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 31
Comparative Analysis by Late Stage Development, H1 2013 32
Comparative Analysis by Mid Clinical Stage Development, H1 2013 33
Comparative Analysis by Early Clinical Stage Development, H1 2013 34
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 35
Products under Development by Companies, H1 2013 36
Products under Development by Companies, H1 2013 (Contd..1) 37
Products under Development by Companies, H1 2013 (Contd..2) 38
Products under Development by Companies, H1 2013 (Contd..3) 39
Products under Development by Companies, H1 2013 (Contd..4) 40
Products under Development by Companies, H1 2013 (Contd..5) 41
Products under Investigation by Universities/Institutes, H1 2013 42
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 43
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 44
Products under Investigation by Universities/Institutes, H1 2013 (Contd..3) 45
Genzyme Corporation, H1 2013 46
Sanofi-Aventis, H1 2013 47
AstraZeneca PLC, H1 2013 48
GlaxoSmithKline plc, H1 2013 49
Inovio Biomedical Corporation, H1 2013 50
Novartis AG, H1 2013 51
Actelion Ltd, H1 2013 52
Eisai Co., Ltd., H1 2013 53
Pfizer Inc., H1 2013 54
Ranbaxy Laboratories Limited, H1 2013 55
Aduro BioTech, H1 2013 56
CEL-SCI Corporation, H1 2013 57
Crucell N.V., H1 2013 58
Hollis-Eden Pharmaceuticals, Inc., H1 2013 59
Mymetics Corporation, H1 2013 60
Cleveland BioLabs, Inc., H1 2013 61
Alnylam Pharmaceuticals, Inc, H1 2013 62
IPCA Laboratories Limited, H1 2013 63
Lipoxen PLC, H1 2013 64
Raptor Pharmaceuticals Corp., H1 2013 65
PolyMedix, Inc., H1 2013 66
Affitech A/S, H1 2013 67
Colby Pharmaceutical Company, H1 2013 68
Bharat Biotech International Limited, H1 2013 69
Jenrin Discovery, Inc., H1 2013 70
Mucosis B.V., H1 2013 71
Protein Potential, LLC, H1 2013 72
Anacor Pharmaceuticals, Inc., H1 2013 73
Telormedix SA, H1 2013 74
Dilafor AB, H1 2013 75
Okairos, H1 2013 76
Ferrer Internacional S.A., H1 2013 77
Chimerix, Inc., H1 2013 78
Phage Biotechnology Corporation, H1 2013 79
Sanaria Inc., H1 2013 80
NovaLead Pharma Pvt. Ltd., H1 2013 81
ImmunoVaccine Technologies Inc., H1 2013 82
Acetylon Pharmaceuticals, Inc., H1 2013 83
Etubics Corporation, H1 2013 84
iBio, Inc., H1 2013 85
PepTcell Limited, H1 2013 86
Genocea Biosciences, Inc., H1 2013 87
Hawaii Biotech, Inc., H1 2013 88
Sigma-Tau Pharmaceuticals, Inc., H1 2013 89
Selecta Biosciences, Inc., H1 2013 90
GlaxoSmithKline Inc., H1 2013 91
Pfenex Inc., H1 2013 92
NeED Pharma s.r.l., H1 2013 93
VLP Biotech, Inc., H1 2013 94
Jomaa Pharma GmbH, H1 2013 95
Assessment by Monotherapy Products, H1 2013 96
Assessment by Combination Products, H1 2013 97
Assessment by Stage and Route of Administration, H1 2013 99
Assessment by Stage and Molecule Type, H1 2013 101
Malaria Therapeutics Drug Profile Updates 244
Malaria Therapeutics Discontinued Products 252
Malaria Therapeutics Discontinued Products (Contd..1) 253
Malaria Therapeutics Dormant Products 254
Malaria Therapeutics Dormant Products (Contd..1) 255
Malaria Therapeutics Dormant Products (Contd..2) 256
Malaria Therapeutics Dormant Products (Contd..3) 257
Malaria Therapeutics Dormant Products (Contd..4) 258

List of Chart


Number of Products under Development for Malaria, H1 2013 21
Products under Development for Malaria Comparative Analysis, H1 2013 22
Products under Development by Companies, H1 2013 23
Products under Investigation by Universities/Institutes, H1 2013 29
Late Stage Products, H1 2013 32
Mid Clinical Stage Products, H1 2013 33
Early Clinical Stage Products, H1 2013 34
Discovery and Pre-Clinical Stage Products, H1 2013 35
Assessment by Monotherapy Products, H1 2013 96
Assessment by Combination Products, H1 2013 97
Assessment by Route of Administration, H1 2013 98
Assessment by Stage and Route of Administration, H1 2013 99
Assessment by Molecule Type, H1 2013 100
Assessment by Stage and Molecule Type, H1 2013 101

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *